During the last ten years, third generation aromatase inhibitors (AIs) have proved to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, it is of great importance to gain insight into these mechanisms. Therefore, the aim of this project was to study the molecular basis for resistance to AIs to unravel new targets for treatment.
|Uddannelser||Molekylærbiologi, (Bachelor/kandidatuddannelse) Kandidat|
|Udgivelsesdato||27 jun. 2014|
|Vejledere||Jesper Thorvald Troelsen & Christina Yde Westmose|